PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $35,265,887 | -23.7% | 1,149,475 | -0.4% | 0.03% | -19.0% |
Q2 2023 | $46,246,735 | -1.5% | 1,154,149 | +0.3% | 0.04% | -6.7% |
Q1 2023 | $46,954,675 | +6.5% | 1,150,568 | +0.8% | 0.04% | +2.3% |
Q4 2022 | $44,069,917 | -26.8% | 1,141,412 | +0.9% | 0.04% | -27.9% |
Q3 2022 | $60,186,000 | -8.3% | 1,131,531 | +0.5% | 0.06% | 0.0% |
Q2 2022 | $65,652,000 | -23.6% | 1,126,100 | +0.0% | 0.06% | -6.2% |
Q1 2022 | $85,910,000 | +27.3% | 1,125,653 | +0.4% | 0.06% | +41.3% |
Q4 2021 | $67,481,000 | +7.6% | 1,121,499 | +0.1% | 0.05% | +2.2% |
Q3 2021 | $62,733,000 | -8.0% | 1,120,232 | -0.3% | 0.04% | -4.3% |
Q2 2021 | $68,169,000 | -13.3% | 1,123,422 | +0.2% | 0.05% | -20.3% |
Q1 2021 | $78,591,000 | +16.2% | 1,121,286 | -0.8% | 0.06% | +13.5% |
Q4 2020 | $67,628,000 | -0.1% | 1,130,151 | +0.3% | 0.05% | -10.3% |
Q3 2020 | $67,711,000 | +14.6% | 1,126,260 | +0.0% | 0.06% | +9.4% |
Q2 2020 | $59,072,000 | +56.8% | 1,125,826 | +0.2% | 0.05% | +29.3% |
Q1 2020 | $37,673,000 | -27.6% | 1,123,562 | -1.5% | 0.04% | -4.7% |
Q4 2019 | $52,012,000 | +19.8% | 1,141,123 | +0.1% | 0.04% | +13.2% |
Q3 2019 | $43,412,000 | -12.4% | 1,140,320 | +0.0% | 0.04% | -11.6% |
Q2 2019 | $49,570,000 | +13.3% | 1,139,793 | -0.8% | 0.04% | +10.3% |
Q1 2019 | $43,733,000 | -11.4% | 1,149,062 | +0.1% | 0.04% | -22.0% |
Q4 2018 | $49,372,000 | -10.3% | 1,147,655 | +2.5% | 0.05% | +6.4% |
Q3 2018 | $55,055,000 | +55.4% | 1,120,152 | +1.4% | 0.05% | +62.1% |
Q2 2018 | $35,420,000 | +4.1% | 1,105,138 | +1.2% | 0.03% | -9.4% |
Q1 2018 | $34,029,000 | -31.8% | 1,092,415 | -0.1% | 0.03% | -30.4% |
Q4 2017 | $49,907,000 | +21.7% | 1,093,259 | +0.1% | 0.05% | +17.9% |
Q3 2017 | $41,009,000 | -21.7% | 1,092,120 | -0.5% | 0.04% | -23.5% |
Q2 2017 | $52,381,000 | +5.6% | 1,098,142 | +1.0% | 0.05% | +2.0% |
Q1 2017 | $49,601,000 | +41.5% | 1,087,752 | +0.2% | 0.05% | +28.2% |
Q4 2016 | $35,056,000 | -5.8% | 1,085,310 | -0.1% | 0.04% | -7.1% |
Q3 2016 | $37,195,000 | +1.5% | 1,086,935 | +0.1% | 0.04% | -2.3% |
Q2 2016 | $36,632,000 | -36.1% | 1,086,050 | +0.3% | 0.04% | -37.7% |
Q1 2016 | $57,371,000 | -31.9% | 1,082,887 | -1.3% | 0.07% | -29.6% |
Q4 2015 | $84,251,000 | +148.9% | 1,097,160 | +33.2% | 0.10% | +139.0% |
Q3 2015 | $33,854,000 | -38.0% | 823,702 | +6.7% | 0.04% | -29.3% |
Q2 2015 | $54,618,000 | -14.7% | 772,309 | +7.2% | 0.06% | -12.1% |
Q1 2015 | $64,017,000 | -16.7% | 720,508 | -16.9% | 0.07% | -18.5% |
Q4 2014 | $76,835,000 | -8.7% | 866,621 | -0.2% | 0.08% | -12.9% |
Q3 2014 | $84,200,000 | +6.3% | 868,757 | +0.8% | 0.09% | +4.5% |
Q2 2014 | $79,179,000 | +80.6% | 861,956 | +37.6% | 0.09% | +71.2% |
Q1 2014 | $43,846,000 | +44.3% | 626,464 | +18.5% | 0.05% | +36.8% |
Q4 2013 | $30,383,000 | +151.2% | 528,500 | +110.0% | 0.04% | +123.5% |
Q3 2013 | $12,096,000 | – | 251,617 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GAGNON SECURITIES LLC | 563,415 | $21,753,453 | 4.80% |
Gagnon Advisors, LLC | 180,331 | $6,962,579 | 4.70% |
Spyglass Capital Management LLC | 868,686 | $33,539,966 | 2.69% |
Tamarack Advisers, LP | 100,000 | $3,861,000 | 1.99% |
ARMISTICE CAPITAL, LLC | 1,892,000 | $73,050,120 | 1.27% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 276,590 | $10,679,140 | 0.99% |
RICE HALL JAMES & ASSOCIATES, LLC | 437,285 | $16,883,574 | 0.97% |
Rock Springs Capital Management LP | 1,032,600 | $39,868,686 | 0.96% |
OUTFITTER FINANCIAL LLC | 25,860 | $998,455 | 0.91% |
Stephens Investment Management Group LLC | 1,168,469 | $45,535,237 | 0.82% |